In many UN member countries, clinical studies on the effectiveness of PAT have been conducted under government supervision and have identified PAT as an effective therapeutic method. The psychedelic-assisted therapy efficacy has been confirmed by numerous scientific studies, for example:
● The U.S. Food and Drug Administration (FDA) granted psychedelic therapy “breakthrough” status — this accelerated research into psychedelics, highlighted their superior effectiveness, and helped legitimize PAT methodology in the eyes of both the public and policymakers.
● French researchers found that symptoms of depression, alcohol and tobacco addiction, and obsessive-compulsive disorder were reduced after just one session of psilocybin-assisted therapy..
● And this one U.S.-based study demonstrated the effectiveness of therapy using LSD and MDMA for patients with anxiety disorders, PTSD, and even anxiety among adults with autism.
● In a 2021 American study, 88% of patients with PTSD reported symptom relief after three MDMA-assisted sessions. Of those, 67% reported full recovery. Meanwhile, the same psychotherapists conducted traditional (non-psychedelic) therapy with a separate control group, where only 32% of participants reported symptom improvement.

Since 2020 up to 2025, 107 new clinical trials on the use of PAT for treating various mental health disorders have been registered on clinicaltrials.gov: 55 in the U.S., 21 in EU countries, 12 in Canada, and 2 in Israel.
Real-life stories and treatment outcomes are publicly available on the official websites of relevant institutions (mostly in English).
Many new psychedelic research centers have been established, including:
● The Centre for Psychedelic Research at Imperial College London, ● The UC Berkeley Center for the Science of Psychedelics, ● Johns Hopkins University, ● King’s College London / Onaya Science, ● University of San Francisco, ● University of Texas, ● and many others.

Organizations and medical professionals are actively studying PAT. Getting familiar with their research can help you stay informed on the latest developments and how PAT may or may not be integrated into your work with veterans:
● Mind Medicine – an Australian association focused on preventing suicide and suffering through clinical PAT application, research, and advocacy, ● Swiss Medical Association for Psychedelic-Assisted and Psycholytic Therapy, ● Ukrainian Psychedelic Research Association (UPRA), ● Multidisciplinary Association for Psychedelic Studies (MAPS), ● American Psychedelic Practitioners Association, ● Board of Psychedelic Medicine and Therapies (BPMT), ● Veterans Exploring Treatment Solutions (VETS), ● And others.

Government-supported programs for recovery, rehabilitation, and treatment of veterans and PTSD survivors also operate in countries such as the USA, Australia, Israel, and Canada. Numerous commercial and nonprofit initiatives use PAT methods to support veterans’ mental health, including:
● Fenix Project – a Ukrainian nonprofit initiative offering psychological recovery for veterans, paramedics, and other combat participants along with their families.● We Honor Veterans – a program by the National Hospice and Palliative Care Organization (Washington, D.C.).● Heroic Hearts Project helps veterans with PTSD access psychedelic programs.● ReConsider – a nonprofit promoting the integration of transformational medicines, including psychedelics, into mental health care.● The Mission Within — a clinical psychedelic retreat providing specialized treatment for PTSD, mTBI, depression, and anxiety, helping participants heal and grow beyond trauma. ● And others.
VETS: Modern Recovery Course – this free course provides veterans with information on how psychedelic therapy can improve their mental health and how to make the most of the experience. It offers insight into the broader landscape of ongoing psychedelic research.

As the evidence base for the therapeutic benefits of psychedelics continues to grow, expanding access to these therapies is becoming increasingly feasible. The scientific community continues to investigate and document the effectiveness and use of psychedelic substances — including PAT — with currently available data showing strong results, especially for severe PTSD and depression.

No. A specially trained and certified psychedelic support provider uses only medical-grade, legal, high-quality substances during the sessions and carefully monitors the process. In this setting, side effects are minimized, and there is no risk of drug addiction.

In sessions guided by a professional PAT therapist (psychedelic support provider), the concept of a “bad trip” does not apply. Intense emotions and encounters with one’s fears are a natural part of the transformation and healing process. The specialist provides continuous guidance and support throughout the journey, helping to navigate all states — making the sessions safe and well-contained.

PAT has a favorable safety profile. The use of medical-grade, high-quality psychoactive substances in a therapeutic setting and at appropriate therapeutic doses is generally safe — both in terms of toxicity and risk of addiction. The pharmacological effects wear off relatively quickly and are not dangerous for most individuals. Moreover, PAT is administered under the supervision of a trained professional, which further enhances safety.
Temporary and mild side effects may occur, including:- muscle tension increased- sweating - reduced appetite - nausea- changes in systolic and diastolic blood pressure- changes in heart rate
Contraindications include conditions where elevated blood pressure poses a significant risk, schizophrenia spectrum disorders, and other psychotic disorders. However, the relationship between PAT and psychotic disorders remains a subject of ongoing debate and research.
It is important to emphasize that PAT is still being actively studied. The use of psychoactive substances carries potential risks, and — as with any form of psychotherapy — there is no approach, including PAT, that is suitable for absolutely everyone.

�� WARNING!!! We strongly advise against conducting such sessions without the supervision of a certified, experienced psychedelic support provider!
The consequences can be unpredictable, with a high risk of serious and irreversible harm to your physical and mental health. Substances obtained from the unregulated market are almost always highly toxic and contaminated, often resulting in severe adverse effects.
Moreover, the therapeutic effect of PAT requires the presence of a psychotherapist with specialized knowledge. Please, seek support only from verified, qualified professionals with formal education and experience specifically in psychedelic-assisted therapy.

PAT involving MDMA and psilocybin is already:
1. Legally permitted and applied in countries such as Israel, the United States, Canada, and Australia.
2. Officially recognized as a breakthrough treatment for PTSD (since 2017) and depression using psilocybin (since 2018).
3. In the summer of 2022, the second Phase 3rd clinical trial of MDMA for PTSD was completed (across 13 clinics in the U.S. and Israel). That same year, the U.S. Presidential Administration officially announced preparations for the broad implementation of the method in 2023–2024.
Since MDMA and psilocybin are currently prohibited in Ukraine, they cannot be legally used in science or medicine. Due to low public awareness, only a few specialists in Ukraine currently apply legal forms of PAT, such as ketamine-assisted psychotherapy.

For PAT to become legally available in Ukraine, the Cabinet of Ministers must reclassify currently banned psychoactive substances, moving them from the list of prohibited substances to the category of strictly controlled ones — as is the case with ketamine.
UPRA (Ukrainian Psychedelic Research Association), which is our partner organization, is actively working toward the legalization of psychedelic-assisted therapy in Ukraine.
You can support PAT advocacy in Ukraine by collaborating with our charitable foundation, Fenix Project, or by participating in the work of UPRA.